Vor Biopharma (VOR) AI Stock Analysis

• Market Cap: $70.52M
• Dividend Yield: N/A
• Average Volume (3M): 229.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: N/A
• EPS Growth: 2.98%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 124,851,550
• 10 Day Avg. Volume: 230,126
• 30 Day Avg. Volume: 229,627
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.25
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $0.32
• Price Target Upside: 113.33% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.

Positive Factors

Clinical Advancements

Trem-cel continues to demonstrate high engraftment rate, shielding from MYLOTARG on-target toxicity with a broader therapeutic window, and early evidence of improved relapse free survival.

Regulatory Progress

FDA does not require additional data to start the Phase III trial and agreed with VOR on its design.

Scientific and Clinical Thesis

The transformative potential of trem-cel and VCAR33 in treating AML/MDS is supported by clinical data, enhancing the company's scientific and clinical thesis.

Negative Factors

Market Conditions

Challenging capital markets and negative pressure on the gene/cell therapy sector have led to significant share count dilution.

Strategic Uncertainty

The decision to downgrade VOR is due to uncertainties regarding the company's pipeline development and business strategies going forward.

Workforce Reduction

A significant reduction in workforce and associated restructuring expenses indicate financial and operational challenges.

Vor Biopharma Business Overview & Revenue Model

Company Description

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Vor Biopharma generates revenue primarily through research and development collaborations, partnerships, and potential future product sales. The company's business model is centered around developing its pipeline of eHSC-based therapies, which are designed to improve the efficacy and safety of existing cancer treatments. Revenue streams may include milestone payments and royalties from strategic partnerships with larger pharmaceutical companies, as well as potential licensing agreements for its proprietary technologies. Additionally, Vor Biopharma may secure funding through government grants or research institutions to support its innovative research initiatives.

Vor Biopharma Financial Statement Overview

Summary

Vor Biopharma shows significant financial strain with zero revenue and consistent losses. The balance sheet indicates declining equity, and cash flow statements reflect persistent cash burn issues, presenting high financial risk.

Income Statement

Vor Biopharma has consistently reported zero revenue, indicating a lack of operational income generation. The company has been operating at a loss for several years, with negative EBIT and net income, highlighting significant profitability challenges.

Balance Sheet

The company maintains a moderate debt-to-equity ratio, which suggests limited leverage. However, the continuous decline in stockholders' equity and total assets since 2020 raises concerns about financial stability and sustainability.

Cash Flow

Vor Biopharma's free cash flow has been consistently negative, indicating cash burn issues. The operating cash flow is also negative, suggesting operational inefficiencies and an inability to cover costs without external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-3.49M	-8.96M	-4.45M	-1.39M
	EBIT
-121.19M	-126.04M	-93.42M	-69.02M	-43.37M
	EBITDA
-121.19M	-114.37M	-90.89M	-67.58M	-41.95M
	Net Income Common Stockholders
-116.91M	-117.86M	-90.77M	-68.78M	-43.34M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
91.93M	137.18M	230.25M	207.47M	48.54M
	Total Assets
142.89M	198.13M	299.37M	242.59M	75.91M
	Total Debt
31.83M	35.66M	38.91M	18.01M	18.29M
	Net Debt
-50.12M	4.30M	-18.79M	-101.79M	-30.25M
	Total Liabilities
46.23M	47.40M	48.76M	26.33M	27.64M
	Stockholders Equity
96.66M	150.72M	250.61M	216.26M	48.27M
Cash Flow		Free Cash Flow
-99.89M	-101.36M	-93.61M	-73.04M	-40.45M
	Operating Cash Flow
-99.66M	-100.29M	-85.14M	-69.14M	-36.29M
	Investing Cash Flow
96.86M	71.01M	-94.09M	-91.65M	-4.16M
	Financing Cash Flow
53.39M	2.94M	117.14M	232.91M	82.53M

Vor Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.73, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 14.59 is Positive, neither overbought nor oversold. The STOCH value of 4.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VOR.

Vor Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.17B	3.59	-42.19%	2.82%	15.05%	-0.04%
SNTI	47 Neutral	$85.75M	―	-116.63%	―	-100.00%	24.59%
ZNTL	46 Neutral	$89.76M	―	-42.83%	―	―	48.92%
ELUT	46 Neutral	$76.83M	―	149.62%	―	-31.04%	11.34%
CCCC	41 Neutral	$100.12M	―	-45.55%	―	98.56%	37.97%
PLRX	37 Underperform	$89.62M	―	-63.22%	―	-100.00%	-26.44%
VOR	33 Underperform	$70.52M	―	-94.52%	―	―	2.98%

Vor Biopharma Corporate Events

Vor Biopharma’s Chief Medical Officer Resigns

On March 31, 2025, Eyal C. Attar, M.D., announced his resignation as Chief Medical Officer of Vor Biopharma Inc., effective April 18, 2025, to pursue a new opportunity. Vor Biopharma plans to enter into a consulting agreement with Dr. Attar for transition services, acknowledging his contributions to the company.

Vor Biopharma Approves Stock Option Repricing Strategy

On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise price of certain options to $1.34 per share, impacting approximately 6.76 million shares. This move aims to motivate and retain employees while avoiding stock dilution or additional cash outlays, with a retention period set until February 3, 2026 or earlier under specific conditions.